Industry News 19 Oct 2026

Akeso Announces Opening of Global Phase II Study of Ivonescimab in First-Line Clear Cell Renal Cell Carcinoma, Including Combination with Cadonilimab

Source: It비즈뉴스 •By itbiznews •1 min read

HONG KONG, Oct. 19, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") and its partner Summit Therapeutics Inc. jointly announced an international multicenter Phase II clinical study (SMT112-216 / AK112-216 / NCT07877194). Built on Akeso's first-in-class immuno-oncology (IO) cor...

This is a short summary. The full story is published by It비즈뉴스.

Read full story at It비즈뉴스

Related news

Limited-Time Offer
Advertise on PharmaJungle - Free for 30 Days

Get your company in front of buyers, manufacturers, and sourcing professionals on PharmaJungle - completely free for your first 30 days.

  • 30 days of free advertising
  • Visibility across all pages
  • Performance report with ad insights
  • No setup or registration fee
Claim Your Free Ad

Exclusive introductory offer for new advertisers

Top sources
A Abnewswire 10 stories
I Indianpharmapost 5 stories
F Finanznachrichten.de 5 stories
K Kalkine Media 4 stories
F FDA 4 stories
PharmaJungle
Buying request

Post your requirement

Get offers from suppliers

  • Reach pharmaceutical suppliers
  • Specify quality standard and quantity
  • Set your shipping preference
  • Receive offers directly
  • Listed on our marketplace

Your product details and requirements may be published on the marketplace.

PharmaJungle

Create a New Buying Request

Fields marked with * are mandatory.

Please enter quantity.
Please select a unit.
Please select quality standard.
Please select request type.
Please provide product specifications.
Please enter additional details.
Please select shipping preference.
Notice: By submitting this buying request, the provided product details and requirements may be published publicly on our marketplace.